TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

surgeons operating

Society of Thoracic Surgeons launches new risk calculators for SAVR after TAVR, other key heart surgeries

STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients. 

April 26, 2024
old elderly couple coffee drink retired love romance man

TAVR, SAVR linked to similar QOL improvements for intermediate-risk patients after five years

TAVR was initially associated with greater benefits than surgery, but that difference faded by the end of the first year.

April 24, 2024
Lars Svensson, MD, PhD

Q&A: Cleveland Clinic’s Lars Svensson previews AATS annual meeting

Svensson, a prominent voice in cardiothoracic surgery, said he has seen a rise in enthusiasm ahead of this year's meeting.

April 23, 2024
doctor examines patient data on their tablet

TAVR or SAVR? ChatGPT could help cardiologists decide

Researchers asked ChatGPT to make treatment decisions for patients with severe aortic stenosis, comparing its answers to the recommendations of a full heart team. 

April 22, 2024
TAVR JenaValve Trilogy Heart Valve System pure AR

Cardiologists make history, perform first-ever transcaval TAVR for pure aortic regurgitation

The 65-year-old male patient presented with a long medical history and many comorbidities, making surgery too risky.

April 18, 2024
The V-Wave intra-atrial shunt to treat heart failure on display on the expo floor at ACC.24. The device was used in one of the late breaking trials at ACC. DF 3

PHOTO GALLERY: Highlights from ACC.24 in Atlanta

ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement. 

April 16, 2024
Video of Howard Herrmann, MD, explaining the details of the SMART trial that looked at TAVR in small annulus and found self-expanding TAVR valves work better in these patients than balloon-expanding TAVR at ACC.24. #ACC24 #ACC2024

Cardiologist highlights key takeaways from SMART trial, which looked at TAVR in small annulus patients

Howard C. Herrmann, MD, principal investigator of the SMART trial, discussed his team's research on self-expanding vs. balloon-expandable TAVR valves in patients with small annuli. 

April 11, 2024
doctor examines patient data on their tablet

TAVR, SAVR both linked to low reintervention rates after five years

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

April 10, 2024